HC Wainwright Issues Pessimistic Outlook for RGLS Earnings

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Equities researchers at HC Wainwright decreased their FY2024 earnings estimates for Regulus Therapeutics in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.86) for the year, down from their previous estimate of ($0.80). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Regulus Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

RGLS has been the subject of several other reports. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock opened at $1.43 on Thursday. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The company has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.81. The company has a market cap of $93.67 million, a PE ratio of -1.34 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

Institutional Investors Weigh In On Regulus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Creative Planning acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at $26,000. SG Americas Securities LLC acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $46,000. Barclays PLC grew its stake in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics in the 2nd quarter worth approximately $136,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.